The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

An extravasation risk rating system introduced for all IV medicines has led to increased patient safety at Birmingham Women’s and Children’s NHS Foundation Trust.